Rhythm Pharmaceuticals, Inc.

NASDAQ:RYTM

Biotechnology

Healthcare
$119.04 +3.57%

+$3.42 today

Market cap
$8.25B
Beta
1.92
P/E (TTM)
-33.3
EPS (TTM)
-$2.98
52W Low $60.80High $122.20

Volume 2.01M

Average 0.81M

RYTM Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Rhythm Pharmaceuticals, Inc.NASDAQ: RYTM

Weighted Avg Shares · Q3 FY2026 · quarter ended Sep 2026

Weighted avg shares grows in line with its trailing trend

Q3 FY2026 weighted avg shares of 69.05M shares rose 7.3% year over year, behind the +7.8% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 0.7% from the prior quarter. Over 3 fiscal years it compounded at +7.6% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +7.3% toward the trailing-twelve-month pace of +7.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
69.05M+0.7% QoQ
Last fiscal yearDec 2025
64.98M+6.5% YoY
LTMSep 2026
68.12M+7.8% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+7.3%——
1 year+6.5%——
3-year CAGR+7.6%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
64.98M USD
Year-over-year change
+6.5%
4-year CAGR
+7.0%

Weighted Avg Shares vs competitors

How RYTM compares with its peers on the latest reported figures

  • RYTM's LTM Sep 2026 weighted avg shares of 68.12M shares is the 3rd highest of the 11 companies compared; the peer median is 45.93M shares.
  • Its year-over-year change of +7.8% is the 6th highest of 11, against a peer median of +8.5%.
  • Over three fiscal years its annual growth of +7.6% compares with a peer median of +4.6%.
RYTM Competitors Peer median
Weighted Avg Shares for RYTM and competitors
Company Period LTM YoY 3-year CAGR
BMRNBioMarin Pharmaceutical Inc.LTM Sep 2026192.71M +0.7%+1.2%
VKTXViking Therapeutics, Inc.LTM Jun 2026114.45M +2.5%+13.6%
RYTMRhythm Pharmaceuticals, Inc.LTM Sep 202668.12M +7.8%+7.6%
GPCRStructure Therapeutics Inc.LTM Jun 202665.7M +14.4%+17.4%
BMEABiomea Fusion, Inc.LTM Mar 202656.46M +55.6%+21.3%
MAZEMaze Therapeutics, Inc.LTM Mar 202646.63M +6.5%-0.6%
SEPNSepterna, Inc.LTM Sep 202645.24M +9.8%—
MBXMBX Biosciences, Inc. Common StockLTM Sep 202644.83M +33.4%+4.6%
BLTEBelite Bio, IncLTM Sep 202638.5M +19.1%+18.9%
BIOABioAge Labs, Inc.LTM Mar 202637.57M +7.3%+1.7%
PTNPalatin Technologies, Inc.LTM Mar 20261.8M -80.8%-61.6%
Peer median (excluding RYTM) 45.93M+8.5%+4.6%

Competitors are the stored peer set for RYTM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue3.15M23.64M77.43M130.13M189.76M
Cost of Revenue599K2.13M9.3M13.37M19.49M
Gross Profit2.56M21.51M68.13M116.76M170.27M
Gross Margin81.0%91.0%88.0%89.7%89.7%
Research & Development104.13M108.63M134.95M237.96M167.34M
Selling, General & Admin68.49M92.03M117.53M144.3M194.94M
Operating Expenses172.61M200.66M252.48M382.26M362.28M
Depreciation & Amortization1.16M1.67M1.76M1.56M1.34M
EBITDA(68.45M)(174.25M)(168.46M)(238.09M)(174.12M)
EBITDA Margin-2170.4%-737.1%-217.6%-183.0%-91.8%
Operating Income(170.06M)(179.16M)(184.36M)(265.5M)(192.02M)
Operating Margin-5391.9%-757.9%-238.1%-204.0%-101.2%
Interest Income447K4.03M13.95M14.71M15.29M
Interest Expense05.2M13.89M20.6M20.58M
Other Income / Expenses100.45M(1.96M)243K5.25M(4.03M)
Income Before Tax(69.61M)(181.12M)(184.11M)(260.26M)(196.04M)
Pre-Tax Margin-2207.1%-766.2%-237.8%-200.0%-103.3%
Income Tax Expense00564K346K497K
Net Income(69.61M)(181.12M)(184.68M)(260.6M)(196.54M)
Net Margin-2207.1%-766.2%-238.5%-200.3%-103.6%
EPS (Basic)(1.37)(3.51)(3.20)(4.34)(3.11)
EPS (Diluted)(1.37)(3.51)(3.20)(4.34)(3.11)
Weighted Avg Shares49.6M52.12M57.67M61M64.98M
Weighted Avg Shares (Diluted)49.6M52.12M57.67M61M64.98M

Rhythm Pharmaceuticals, Inc.

NASDAQ:RYTM

Intrinsic Alpha fair value

Locked

Current Price

$119.04

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.